Notice of References Cited Application/Control No. 10/580,542 Examiner ELLY-GERALD STOICA Applicant(s)/Patent Under Reexamination WALLACH ET AL. Page 1 of 2

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	Α	US-2003/0092044	05-2003	Goddard et al.	435/6
*	В	US-6,010,853	01-2000	Kanteti et al.	435/6
	С	US-			
	D	US-			
	Е	US-			
	F	US-			
	G	US-			
	Н	US-			
	1	US-			
Char	igg(s) abblied			
to do	сұт	ertis-			
/A.,	.P <u>.</u> /	US-			
7/21	/ I M	IUS-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	Ν	WIPO 03/087374	10-2003	ISRAEL	Wallach et al.	C12N 15/12
	0					
	Ρ					
	Ø					
	R					
	Ø					
	Т					

NON-PATENT DOCUMENTS

	HON I ALEM BOODINENTO						
*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)					
	U	Joske DJL,Chronic myeloid leukaemia: the evolution of gene-targeted therapy. Med. J. Aust., 189,277-282, 2008					
	V	Richardson et al, Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector. Gene therapy, 5, 635-644, 1998.					
	w	Lo et al. Intracellular Antibodies (Intrabodies) and Their Therapeutic Potential. Handb. Exp Pharmacol. 181, 343-373, 2008;Y.Chernajovsky, A.Nissim (eds.) Therapeutic Antibodies, Springer-Verlag Berlin Heidelberg 2008.					
	х	Katayama et al. A possible role for the loss of CD27-CD70 interaction in myelomagenesis. Br J Haematol. 120, 223-234, 2003.					

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.